Dr. Lal PathLabs Q1 FY27: Revenue up 19.1% to ₹798 Cr, Declares 50% Interim Dividend
Dr. Lal PathLabs reported Q1 FY27 revenue of ₹798 crore, up 19.1% YoY, its highest growth in 4 years. PAT increased 27.2% to ₹170 crore. The company declared a 50% interim dividend (₹5/share). Acquisitions include Sunshine Healthcare (Ghana) and Neuome Technologies. Management expects CGHS/ECHS price hike benefits for 2-3 quarters.
The announcement includes strong financial performance, strategic acquisitions in diagnostics and healthcare innovation, and a dividend payout, all of which are material events for investors.
The company reported strong financial results with significant revenue and profit growth, the highest quarterly growth in four years, and declared an interim dividend, all positive indicators.
Dr. Lal PathLabs announced its financial results for the first quarter of FY27, reporting a revenue of ₹798 crore, marking a significant year-on-year growth of 19.1%. This growth rate is the highest quarterly growth achieved in the last four years, driven by an 8.2% increase in patient volumes (8.2 million) and a 10.7% rise in sample volumes (25.9 million).
The company's performance is underpinned by three key pillars: Scientific Leadership, Enhanced Patient Experience, and Operational Excellence. Under Scientific Leadership, 116 new tests were launched, including 4 first-in-India tests, and advanced diagnostics were expanded. For Enhanced Patient Experience, a GenAI Patient Bot on WhatsApp, SwasthAI, was introduced. Operational Excellence initiatives led to industry-leading TATs for Whole Exome Sequencing and Express Whole Exome Sequencing, with routine testing delivered within 3 hours for 90% of walk-in patients.
Financially, Profit Before Tax (PBT) rose by 26.3% to ₹229 crore, and Profit After Tax (PAT) grew by 27.2% to ₹170 crore. EBITDA stood at ₹247 crore, a 28.7% increase from the previous year, with an EBITDA margin of 31.0%. Earnings Per Share (EPS) increased to ₹10.1 from ₹7.9.
The company also announced two board-approved acquisitions: 80% equity in Sunshine Healthcare Limited, Ghana, for up to GHS 45.6 million, and 30% equity in Neuome Technologies Private Limited for up to ₹3.5 crore. Furthermore, the Board of Directors declared an interim dividend of 50% (₹5 per share).
Management indicated that the CGHS and ECHS price increases contributed 2-3% to overall revenue and are expected to continue for the next 2-3 quarters. While the company is evaluating a potential price hike later in the year, it remains focused on sustainable revenue growth, potentially leaning towards mid-teens growth for the fiscal year.
What to do with a filing like this
Dr. Lal Path Labs Ltd. filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Lal Path Labs Ltd.. Read the original for the full detail.